n.marsden
TL1 Member · Munich, DE
Joined after a search result brought me to one of the reconstitution pages. Stayed for the tone.
Joined 12 April 2025 · last posted 14h
24 posts, newest first. Showing up to 150.
-
Follow-up: Sleep quality changes during weight loss Replied, post #81 · Wellbeing › Sleep · 27 Jul 2026 · 16 likes Sleep quality versus quantity: some people report changes to sleep duration; others report changes to sleep quality without duration change. Both can matter for…
-
Here for the analytics and not much else Replied, post #58 · Lounge › Introductions · 19 Jul 2026 · 0 likes Six months of lurking, finally posting. The thing that persuaded me to join was the public moderation log — I have not seen another community publish its own reversals.
-
Tracking a shortage from primary sources rather than rumour Replied, post #18 · Access › Shortages · 22 May 2026 · 2 likes Post #15 and I disagree about the size of the effect, not about the direction. Manufacturer allocation decisions during a shortage are commercial and are rarely…
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #46 · Compounds › Tirzepatide · 13 May 2026 · 0 likes On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent…
-
Reused chromatograms across lots: how to spot it — what changed since Replied, post #31 · Analytics › COA interpretation · 14 Apr 2026 · 0 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
-
Spike-and-recover accuracy for a peptide assay Replied, post #118 · Analytics › Method validation · 11 Apr 2026 · 23 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number.…
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #77 · Lounge › Introductions · 15 Mar 2026 · 0 likes Six months of lurking, finally posting. The thing that persuaded me to join was the public moderation log — I have not seen another community publish its own reversals.
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #10 · Lounge › Introductions · 7 Mar 2026 · 9 likes Six months of lurking, finally posting. The thing that persuaded me to join was the public moderation log — I have not seen another community publish its own reversals.
-
Introducing myself: pharmacist, sceptic, reluctant participant Replied, post #3 · Lounge › Introductions · 9 Jan 2026 · 0 likes New, no scientific background at all, and slightly intimidated by the first three topics I opened. Is there a sensible on-ramp for someone who is here for practical…
-
Storing lyophilised material long term: what governs the shelf life Replied, post #20 · Practice › Storage & stability · 9 Jan 2026 · 0 likes Temperature excursions: if a vial sat at room temperature for a time, the question is whether the excursion was long enough to cause damage. Hours at room temperature…
-
[2026 update] Long-time reader, first-time poster Replied, post #28 · Lounge › Introductions · 26 Nov 2025 · 4 likes Welcome: the response to introductions is usually welcome. People will reply to introduce themselves back or to let you know they are glad you are here. Small point,…
-
Pen dose counters: what a click does and does not guarantee Replied, post #58 · Devices › Pens & autoinjectors · 16 Nov 2025 · 21 likes Pen confusion between compounds: if you are using multiple pens or alternating pens, confirming you have the correct pen before injection prevents administration…
-
Follow-up: The lowest dose that does anything: is that a real question? Replied, post #70 · Practice › Dosing & titration · 1 Nov 2025 · 30 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #22 · Compounds › Semaglutide · 7 Oct 2025 · 0 likes Post #19 answers the question as asked. The question underneath it is different. Research-use-only semaglutide is not a licensed medicine, is not manufactured to…
-
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Replied, post #2 · Compounds › Semaglutide · 5 Oct 2025 · 0 likes Quietly grateful for the plain phrasing. Not every thread gets that.
-
Tracking that stops updating and then resumes — the long version Replied, post #19 · Sourcing › Logistics · 27 Sep 2025 · 24 likes A tracking gap at a customs facility is the most common cause of an unexpectedly long transit and the segment nobody has visibility of. I would put a moderate…
-
Why the timeline is on the right and not the left Replied, post #16 · Meta › Site feedback · 10 May 2025 · 0 likes Post #13 is right about the mechanism and I think understates the practical bit. Accessibility: screen readers, keyboard navigation, contrast, font size — if something…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #23 · Sourcing › Independent verification · 28 Apr 2025 · 4 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…
-
Research-use-only labelling: what it means and what it does not — the long version Replied, post #137 · Sourcing › Regulatory · 25 Apr 2025 · 0 likes Practical note on Research-use-only labelling: write down what you expect before you look. The number of times I have found what I went looking for is higher than…
-
When "no data" is the complete and final answer Replied, post #145 · Compounds › Other compounds · 11 Apr 2025 · 7 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
-
Scheduled maintenance and what will be unavailable Replied, post #78 · Meta › Announcements · 19 Mar 2025 · 12 likes Posting my scheduled maintenance numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a…
-
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #13 · Compounds › Semaglutide · 6 Nov 2024 · 0 likes I read post #9 twice before replying, because I had assumed the opposite. Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg…
-
A rising related-substance total over six months: degradation or method drift? Replied, post #6 · Analytics › Impurities & related substances · 24 Aug 2024 · 4 likes Post #4 and I disagree about the size of the effect, not about the direction. An observation about rising related-substance that I cannot explain and am posting anyway,…
-
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #35 · Practice › Dosing & titration · 7 Jul 2024 · 3 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…